1、 NISHIOKA T, SHINOHARA M, TANIMOTO N, et al. Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis[J]. Dermatololgy,2012,224(1):20-21. NISHIOKA T, SHINOHARA M, TANIMOTO N, et al. Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis[J]. Dermatololgy,2012,224(1):20-21.
2、 LIMA-Martínez M M, GUERRA-Alcalá E, CONTRERAS M, et al.One year remission of type 1 diabetes mellitus in a patient treated with sitagliptin[J]. Endocrinol Diabetes Metab Case Rep,2014(2014):140072. LIMA-Martínez M M, GUERRA-Alcalá E, CONTRERAS M, et al.One year remission of type 1 diabetes mellitus in a patient treated with sitagliptin[J]. Endocrinol Diabetes Metab Case Rep,2014(2014):140072.
3、 BUZZETTI R, POZZILLI P, FREDERICH R, et al. Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA)[J]. Diabetes Metab Res Rev,2015,32(3):289-296. BUZZETTI R, POZZILLI P, FREDERICH R, et al. Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA)[J]. Diabetes Metab Res Rev,2015,32(3):289-296.
4、 SHAH P, ARDESTANI A, DHARMADHIKARI G, et al. The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization[J]. J Clin Endocrinol,2013,98(7):E1163-E1172. SHAH P, ARDESTANI A, DHARMADHIKARI G, et al. The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization[J]. J Clin Endocrinol,2013,98(7):E1163-E1172.
5、 JELSING J,VRANG N,van WITTELOOSTUIJN S B,et al. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice[J]. J Clin Endocrinol,2012,214(3):381-387. JELSING J,VRANG N,van WITTELOOSTUIJN S B,et al. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice[J]. J Clin Endocrinol,2012,214(3):381-387.
6、 JOHASEN O E, BOEHM B O, GRILL V, et al. β-Cell function in latent autoimmune diabetes in adults treated with linagliptin vs glimepiride: exploratory results from a 2-year double-blind randomized controlled study[J]. Diabetologia,2012(55):S67-S68. JOHASEN O E, BOEHM B O, GRILL V, et al. β-Cell function in latent autoimmune diabetes in adults treated with linagliptin vs glimepiride: exploratory results from a 2-year double-blind randomized controlled study[J]. Diabetologia,2012(55):S67-S68.
7、 马燕,冯凯,李伟,等.起始应用胰岛素治疗对成人隐匿性自身免疫性糖尿病患者胰岛功能影响的回顾性分析,中国全科医师杂志[J]. 2016,15,(5):356-360. 马燕,冯凯,李伟,等.起始应用胰岛素治疗对成人隐匿性自身免疫性糖尿病患者胰岛功能影响的回顾性分析,中国全科医师杂志[J]. 2016,15,(5):356-360.
8、 BROPHY S, BRUNT H, DAVIES H,et al. Interventions for latent autoimmune diabetes (LADA) in adults[J]. Cochrane Database Syst Rev,2011,7(3):92. BROPHY S, BRUNT H, DAVIES H,et al. Interventions for latent autoimmune diabetes (LADA) in adults[J]. Cochrane Database Syst Rev,2011,7(3):92.
9、 DUVNJAK L, BLASLOV K,Vu?i?L M, et al. Persons with latent autoimmune diabetes in adults express higher dipeptidyl peptidase-4 activity compared to persons with type 2 and type 1 diabetes[J]. Diabetes Res Clin Pract,2016(121):119-126. DUVNJAK L, BLASLOV K,Vu?i?L M, et al. Persons with latent autoimmune diabetes in adults express higher dipeptidyl peptidase-4 activity compared to persons with type 2 and type 1 diabetes[J]. Diabetes Res Clin Pract,2016(121):119-126.
10、 CASROUGE A,DECALF J,AHLOULAY M, et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV[J]. J Clin Invest,2011,121(12):308-317. CASROUGE A,DECALF J,AHLOULAY M, et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV[J]. J Clin Invest,2011,121(12):308-317.
11、 MATTEUCCI E, GHIMENTI M, DI B S, et al. Altered proportions of naive, central memory and terminally differentiated central memory subsets among CD4+ and CD8+ T cells expressing CD26 in patients with type 1 diabetes[J]. J Clin Immunol, 2011,31(6):977-984. MATTEUCCI E, GHIMENTI M, DI B S, et al. Altered proportions of naive, central memory and terminally differentiated central memory subsets among CD4+ and CD8+ T cells expressing CD26 in patients with type 1 diabetes[J]. J Clin Immunol, 2011,31(6):977-984.
12、 KIM J, NIAN C, MCINTOSH C H S. Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and-independent pathways[J]. Diabetes, 2010,59(7):1739-1750. KIM J, NIAN C, MCINTOSH C H S. Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and-independent pathways[J]. Diabetes, 2010,59(7):1739-1750.
13、 LAUGESEN E, ?STERGAARD J A, LESLIE R D G. Latent autoimmune diabetes of the adult: current knowledge and uncertainty[J]. Diabet Med,2015,32(7):843-852. LAUGESEN E, ?STERGAARD J A, LESLIE R D G. Latent autoimmune diabetes of the adult: current knowledge and uncertainty[J]. Diabet Med,2015,32(7):843-852.
14、 ZHOU Z,XIANG Y,JI L,et al. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study[J]. Diabetes,2013,62(2):543-550. ZHOU Z,XIANG Y,JI L,et al. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study[J]. Diabetes,2013,62(2):543-550.
